174060-98-1Relevant articles and documents
Hepatitis C Virus Inhibitors
-
Paragraph 2226-2227; 2228-2229, (2015/02/25)
The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such combinations, and methods for inhibiting the function of the NS5A protein.
Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
-
, (2008/06/13)
Dipeptidyl peptidase IV (DP 4) inhibiting compounds are provided having the formula where x is 0 or 1 and y is 0 or 1 (provided that x=1 when y=0 and x=0 when y=1); n is 0 or 1; X is H or CN; and wherein R1, R2, R3 and R4 are as described herein. A method is also provided for treating diabetes and related diseases, especially Type II diabetes, and other diseases as set out herein, employing such DP 4 inhibitor or a combination of such DP 4 inhibitor and one or more of another antidiabetic agent such as metformin, glyburide, troglitazone, pioglitazone, rosiglitazone and/or insulin and/or one or more of a hypolipidemic agent and/or anti-obesity agent and/or other therapeutic agent.
Histidine derivatives
-
, (2008/06/13)
Compounds of the formula STR1 wherein R, R1, R2, R3 and R4 represent certain specified substituent groups. The compounds exhibit activity in the reserpine induced hypothermia test.
